Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05060588

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05060588
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05060588. Randomized; triple masking; primary purpose treatment. Start 2021-10 (anticipated); primary completion 2022-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
Condition
Hypertension
Intervention (Drug)
Sacubitril/Valsartan 49/51mg/Tab
Intervention (Drug)
Valsartan 80mg/Tab
Lead sponsor
Qingdao Central Hospital (class: other)

Record details

Record id
cardio:ct-nct05060588
Content hash
e0591874990c20d7984c50f1ca33e9115eccc1b53c743efa2d56587c087f99c0